• TECPR1 Tubulation Repairs Lysosomes Under Energy Stress

  2026-09-18

  A 2026 Cell Research study identifies TECPR1 as a lysosomal repair factor that works with PI4P and KIF1A to remove damaged membrane through tubulation during energy stress. The findings connect lysosome membrane repair with lipid metabolism, cellular survival, and liver injury in a metabolic-associated fatty liver disease model.

• Rimonabant (SR141716) in CB1 Research

  2026-09-17

  Rimonabant (SR141716) gives researchers a selective CB1 blockade strategy for separating receptor-driven withdrawal, appetite, inflammation, and neurobehavioral effects. This workflow-focused guide translates sex-aware rat findings into practical dosing, assay, formulation, and troubleshooting decisions.

• CGK733 in TP53-Mutant Glioblastoma Research

  2026-09-17

  CGK733 is a useful chemical probe for examining how DNA-damage signaling intersects with iron-dependent ferroptosis in TP53-mutant glioblastoma. This article translates recent FTH–ITCH findings into a practical, hypothesis-driven assay strategy.

• Catalpol, Aerobic Glycolysis, and Liver Fibrosis

  2026-09-16

  A 2024 Phytomedicine study identifies hepatic stellate-cell glycolysis as a mechanistic target of Catalpol in carbon tetrachloride-induced liver fibrosis. By combining target-engagement assays with metabolic, cellular, and animal analyses, the work links EphA2/FAK/Src signaling to fibrogenic metabolic reprogramming and provides a framework for mechanism-led liver fibrosis research.

• L-Phenylephrine for α1A Signaling Workflows

  2026-09-16

  Build reproducible α1A-focused assays with L-Phenylephrine for cardiomyocyte stress, neural progenitor, and vascular-response studies. A sex-aware cardiovascular framework helps separate receptor activity from baroreflex, hormone, and formulation effects.

• AZD3463: Designing Better ALK Assays

  2026-09-15

  AZD3463 is an ALK/IGF1R inhibitor with strong relevance to neuroblastoma signaling studies. This article provides an assay-centered framework that connects compound identity, pathway readouts, TSSK2 kinase-screening lessons, and translational interpretation without conflating biochemical potency with cellular response.

• RNF166, PARylated Angiomotins, and YAP in CRC

  2026-09-15

  The reference study identifies RNF166 as an E3 ubiquitin ligase that recognizes tankyrase-modified, poly-ADP-ribosylated angiomotins and promotes their destabilization, thereby activating YAP in colorectal cancer. Its domain-mapping, inhibitor, and rescue experiments connect PARylation-dependent substrate recognition to Hippo pathway dysregulation and provide a useful framework for preserving phosphorylation-dependent readouts during follow-up studies.

• Dual SMAD and Wnt Inhibition for iPSC-RGCs

  2026-09-14

  Chavali and colleagues developed a chemically defined, non-genetic method for directing human induced pluripotent stem cells toward retinal ganglion cells through coordinated SMAD and canonical Wnt inhibition. The approach improves differentiation consistency and enables high-purity RGC production, strengthening experimental models for glaucoma and related neurodegenerative disease research.

• Sphingolipid Inhibition Protects Against Ferroptosis

  2026-09-14

  Liu et al. showed that blocking de novo sphingolipid synthesis with myriocin protects neuronal HT22 cells from erastin- or glutamate-induced ferroptosis through HIF-1 activation, rather than by restoring glutathione. The study identifies HIF1α stabilization and metabolic remodeling as a mechanistic basis for neuroprotection and provides a framework for testing ferroptosis-modifying interventions.

• Bufuralol hydrochloride in Intestinal PK Models

  2026-09-13

  Bufuralol hydrochloride connects human intestinal exposure modeling with β-adrenergic pharmacology, offering a practical way to separate epithelial handling from receptor-level effects. A staged 3D-organoid, 2D-monolayer, and functional response workflow helps researchers investigate metabolism, transport, and partial agonist behavior without treating the compound as a purely neutral blocker.

• 6-Thioguanine Blocks EV71 via BIRC3-Linked Autophagy

  2026-09-12

  The 2025 BMC Microbiology study identifies 6-thioguanine as an in vitro inhibitor of EV71 replication and links this activity to reduced BIRC3-mediated complete autophagy. Its high apparent selectivity in HT-29 cells supports further antiviral investigation, while the single-cell-model design leaves important questions about mechanism, genotype coverage, pharmacology, and clinical translation.

• MOG (35-55) and the Next Era of EAE Translation

  2026-09-11

  MOG (35-55) is more than an established EAE inducer: it is a strategic platform for connecting antigen-specific neuroinflammation with emerging immune-signaling mechanisms. By pairing a defined myelin oligodendrocyte glycoprotein peptide with the PARP7–STAT1/STAT2 axis, translational researchers can build more informative autoimmune disease models while maintaining appropriate boundaries around clinical interpretation.

• Superoxide Dismutase Activity Assay Kit Guide

  2026-09-11

  The Superoxide Dismutase (SOD) Activity Assay Kit (SKU K2035) provides a colorimetric way to quantify functional SOD activity in biological fluids by measuring inhibition of WST-1 reduction. It is intended for controlled research workflows, including oxidative stress studies, and should not be used for diagnostic, medical, or clinical decisions.

• Sumatriptan Metabolism Revisited: CYP and MAO Findings

  2026-09-10

  The reference study revisits the accepted view that sumatriptan is metabolized mainly through monoamine oxidase A (MAO A), showing that selected cytochrome P450 enzymes also produce N-desmethyl and N,N-didesmethyl metabolites. Its recombinant-enzyme and HPLC–MS design provides a useful framework for separating CYP-mediated demethylation from MAO-mediated oxidative deamination in drug-metabolism research.

• Dual SMAD/Wnt Inhibition for iPSC-Derived RGCs

  2026-09-10

  Chavali et al. developed a chemically defined, non-genetic strategy for directing induced pluripotent stem cells toward retinal ganglion cells through coordinated inhibition of SMAD and canonical Wnt signaling. The resulting workflow improves lineage purity and reproducibility, providing a useful platform for glaucoma modeling, disease mechanism studies, and evaluation of RGC-directed interventions.

8493 records 1/567 page Next 12345 下5页 Last page